OVERVIEW

New and Emerging Treatment Options for Refractory HER2+ Metastatic Breast Cancer is organized by Prime Education, LLC.

Release Date: January 10, 2020
Expire Date: January 10, 2021

Estimated Duration: 1 hour 15 min

Accreditation:
Physician Credit Designation Statement:
PRIME® designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Interprofessional Teams:
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Nurse Practitioner Accreditation Statement:
This activity is approved for 1.25 contact hours of continuing education (which includes 1 hour of pharmacology) by the American Association of Nurse Practitioners.
Physician Assistant Accreditation Statement
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation
Pharmacist Accreditation Statement:
This Application-based activity has been approved for 1.25 contact hours (0.125 CEUs) by PRIME® for pharmacists.
Nurse Accreditation Statement:
PRIME® designates this activity for 1.25 contact hours.

Overview:
Treatment of HER2+ metastatic breast cancer (MBC) has significantly improved with the introduction of HER2-targeted agents. However, there is still a need for alternative treatments for patients who progress through multiple lines of therapy unsuccessfully. Emerging evidence suggests that novel agents may provide options for these patients.

Breast cancer experts Dr. Joyce O'Shaughnessy and Dr. Sara Tolaney offer their perspectives on the latest evidence and evolving guidelines, as well as insight on the emerging treatment approaches for difficult-to-treat patient populations with HER2+ MBC. In this interactive video activity, users can navigate through the list of questions to hear the expert discussion supported by evidence-based slides.

Learning Objectives:
• Assess current safety and efficacy data of emerging novel agents for therapeutic decision-making in heavily pretreated patients with HER2+ metastatic breast cancer (MBC)
• Apply evidence-based approaches in therapeutic decision-making for difficult-to-treat patient populations with HER2+ MBC, including sequencing and combination therapies
• Integrate team-based strategies to optimize treatment decisions for patients with recurrent or trastuzumab-resistant HER2+ MBC